Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.42 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400357 | 1.00 | KMT2A (0.54) | KMT2AEPHX2CASP3OPRD1FABP5 | |
| SCHEMBL12391727 | 0.95 | KMT2A (0.57) | KMT2AEPHX2CASP3OPRD1FABP5 | |
| SCHEMBL29470973 | 0.95 | KMT2A (0.57) | KMT2AEPHX2CASP3OPRD1FABP5 | |
| SCHEMBL26352259 | 0.89 | KMT2A (0.51) | KMT2AEPHX2CASP3OPRD1CXCR2 | |
| SCHEMBL27072523 | 0.89 | KMT2A (0.51) | KMT2AEPHX2CASP3OPRD1CXCR2 | |
| SCHEMBL21689327 | 0.88 | KMT2A (0.55) | KMT2AEPHX2CASP3OPRD1FABP5 | |
| SCHEMBL21614492 | 0.88 | KMT2A (0.55) | KMT2AEPHX2CASP3OPRD1FABP5 | |
| SCHEMBL1667739 | 0.87 | KMT2A (0.62) | KMT2AEPHX2CASP3OPRD1FABP5 | |
| SCHEMBL30877982 | 0.87 | KMT2A (0.62) | KMT2AEPHX2CASP3OPRD1FABP5 | |
| SCHEMBL31309934 | 0.87 | KMT2A (0.62) | KMT2AEPHX2CASP3OPRD1FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024235132-A9 | COMPOUND HAVING BIOLOGICAL ACTIVITY, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-06-19 | — | — | WO | disclosed |
| WO-2024235128-A9 | ANTIBODY-DRUG CONJUGATE AND PREPARATION METHOD AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-06-19 | — | — | WO | disclosed |
| WO-2025051241-A1 | MACROCYCLIC COMPOUND AND ANTIBODY-DRUG CONJUGATE THEREOF | 劲方医药科技(上海)股份有限公司 | 2025-03-13 | — | — | WO | disclosed |
| WO-2024235132-A1 | COMPOUND HAVING BIOLOGICAL ACTIVITY, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-11-21 | — | — | WO | disclosed |
| WO-2024235128-A1 | ANTIBODY-DRUG CONJUGATE AND PREPARATION METHOD AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-11-21 | — | — | WO | disclosed |
| WO-2024140903-A1 | COMPOSITION OF CD40-BINDING MOLECULE AND PHARMACEUTICAL USE THEREOF | 苏州盛迪亚生物医药有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-118236514-A | Antibody-glucocorticoid conjugates and uses thereof | 津药生物科技（天津）有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118215676-A | Specific conjugation of antibody drug conjugates | 杭州多禧生物科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-111228511-B | Anti-HER 3 antibody-drug conjugates | 第一三共株式会社 | 2024-06-18 | — | — | CN | disclosed |
| CN-111228510-B | Anti-TROP 2 antibody-drug conjugates | 第一三共株式会社 | 2024-06-18 | — | — | CN | disclosed |
| WO-2022135332-A1 | STEROID CONJUGATE | 映恩生物制药（苏州）有限公司 | 2022-06-30 | — | — | WO | disclosed |
| CN-113905767-A | Traceless linkers and protein conjugates thereof | 里珍纳龙药品有限公司 | 2022-01-07 | — | — | CN | disclosed |
| US-10973924-B2 | Antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-04-13 | — | — | US | disclosed |
| CN-112533951-A | anti-MSR 1 antibodies and methods of use thereof | 里珍纳龙药品有限公司 | 2021-03-19 | — | — | CN | disclosed |
| WO-2021001697-A1 | NOVEL BORONIC ACID CONTAINING PEPTIDOMIMETICS AS MALARIAL SERINE PROTEASE INHIBITORS | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2021-01-07 | — | — | WO | disclosed |
| CN-112004557-A | Steroid compounds and antibody conjugates thereof | 里珍纳龙药品有限公司 | 2020-11-27 | — | — | CN | disclosed |
| CN-111228511-A | anti-HER 3 antibody-drug conjugates | 第一三共株式会社 | 2020-06-05 | — | — | CN | disclosed |
| CN-111228510-A | anti-TROP 2 antibody-drug conjugates | 第一三共株式会社 | 2020-06-05 | — | — | CN | disclosed |
| CN-106163559-B | anti-HER 3 antibody-drug conjugates | 第一三共株式会社 | 2020-02-18 | — | — | CN | disclosed |
| CN-105849126-B | anti-TROP 2 antibody-drug conjugates | 第一三共株式会社 | 2020-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10973924-B2 | Antibody-drug conjugate | LANCL2, LANCL1, LCLAT1 | KMT2A 588/4885EPHX2 2444/4885CASP3 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.